|
JP4776843B2
(ja)
|
1999-10-01 |
2011-09-21 |
イムノゲン インコーポレーティッド |
免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US7700715B2
(en)
|
2000-11-27 |
2010-04-20 |
Minerva Biotechnologies Corporation |
Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
|
|
DK1551876T3
(da)
*
|
2002-10-16 |
2011-06-14 |
Purdue Pharma Lp |
Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
|
|
JP2007531505A
(ja)
*
|
2002-11-27 |
2007-11-08 |
ミネルバ バイオオテクノロジーズ コーポレーション |
癌（ｍｕｃ１）の診断および治療のための技術および組成物
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
NZ551180A
(en)
*
|
2004-06-01 |
2009-10-30 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
EP1848804B1
(en)
*
|
2005-01-28 |
2011-10-05 |
Ramot at Tel Aviv University, Ltd. |
Anti-muc1 alpha beta antibodies
|
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7989595B2
(en)
*
|
2005-06-20 |
2011-08-02 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US8252740B2
(en)
*
|
2006-01-27 |
2012-08-28 |
The University Of Mississippi Medical Center |
Thermally-targeted delivery of medicaments including doxorubicin
|
|
EP2012832A2
(en)
*
|
2006-04-14 |
2009-01-14 |
Celsense, Inc. |
Methods for assessing cell labeling
|
|
PL2155248T3
(pl)
|
2007-04-12 |
2015-12-31 |
Brigham & Womens Hospital Inc |
Celowanie w ABCB5 w terapii nowotworowej
|
|
PE20090245A1
(es)
|
2007-05-08 |
2009-03-17 |
Genentech Inc |
Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
|
|
PT2474557E
(pt)
|
2007-07-16 |
2014-12-03 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
|
PE20140625A1
(es)
|
2007-07-16 |
2014-05-29 |
Genentech Inc |
ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
|
|
DK2657253T3
(en)
|
2008-01-31 |
2017-10-09 |
Genentech Inc |
Anti-CD79b antibodies and immune conjugates and methods of use
|
|
NZ587706A
(en)
|
2008-03-18 |
2012-12-21 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
ES2796111T3
(es)
|
2008-11-14 |
2020-11-25 |
Brigham & Womens Hospital Inc |
Métodos terapéuticos relacionados con células madre cancerosas
|
|
US11542328B2
(en)
|
2008-11-14 |
2023-01-03 |
The Brigham And Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
|
AU2014271278B2
(en)
*
|
2010-03-26 |
2017-01-19 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to MUC16 and methods of use thereof
|
|
CA2793753C
(en)
*
|
2010-03-26 |
2018-06-05 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
|
WO2011133555A2
(en)
|
2010-04-20 |
2011-10-27 |
The Research Foundation Of State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
|
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
|
WO2012106368A2
(en)
|
2011-01-31 |
2012-08-09 |
The Regents Of The University Of California |
Methods for inhibiting prostate cancer
|
|
CN104203982B
(zh)
|
2011-10-28 |
2018-08-31 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
|
GB201213858D0
(en)
*
|
2012-08-03 |
2012-09-19 |
Mab Design Ltd |
Method
|
|
AU2013302620B2
(en)
*
|
2012-08-14 |
2018-08-02 |
Minerva Biotechnologies Corporation |
Stem cell enhancing therapeutics
|
|
DK2839860T3
(da)
|
2012-10-12 |
2019-06-17 |
Medimmune Ltd |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
US9963515B2
(en)
|
2013-04-29 |
2018-05-08 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
CN106132992B
(zh)
*
|
2014-01-29 |
2020-08-07 |
达娜-法勃肿瘤研究所公司 |
针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
|
|
EP4050103A1
(en)
*
|
2014-04-07 |
2022-08-31 |
Minerva Biotechnologies Corporation |
Anti-nme antibody
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2979671C
(en)
|
2014-09-23 |
2020-03-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
PE20170908A1
(es)
|
2014-10-29 |
2017-07-12 |
Teva Pharmaceuticals Australia Pty Ltd |
VARIANTES DE INTERFERON a2b
|
|
EP3256494A4
(en)
|
2015-02-10 |
2018-12-05 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies
|
|
KR102618312B1
(ko)
|
2015-03-17 |
2023-12-28 |
메모리얼 슬로안 케터링 캔서 센터 |
항muc16 항체 및 그의 용도
|
|
US10722523B2
(en)
|
2015-03-17 |
2020-07-28 |
The Regents Of The University Of California |
Chemoimmunotherapy for epithelial cancer
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
IL308735A
(en)
|
2015-07-01 |
2024-01-01 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
WO2017096247A1
(en)
|
2015-12-04 |
2017-06-08 |
Mayo Foundation For Medical Education And Research |
Methods and vaccines for inducing immune responses to multiple different mhc molecules
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
CN105950647A
(zh)
*
|
2016-05-16 |
2016-09-21 |
浙江理工大学 |
一种高效表达与制备外分泌型人源ca125的方法
|
|
JP2019524706A
(ja)
|
2016-07-08 |
2019-09-05 |
ジェネンテック， インコーポレイテッド |
Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
|
|
JP7241677B2
(ja)
|
2016-07-19 |
2023-03-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｃｄ４７併用療法
|
|
US10617773B2
(en)
|
2016-08-05 |
2020-04-14 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
CN112533957B
(zh)
|
2018-06-04 |
2026-01-16 |
普瑞赛格恩公司 |
Muc16特异性嵌合抗原受体及其用途
|
|
EP3920693A4
(en)
|
2019-02-04 |
2022-10-05 |
Minerva Biotechnologies Corporation |
ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
|
|
JP2023530039A
(ja)
|
2020-06-08 |
2023-07-12 |
ミネルバ バイオテクノロジーズ コーポレーション |
抗ｎｍｅ抗体および癌または癌転移の治療方法
|
|
CA3183682A1
(en)
|
2020-06-26 |
2021-12-30 |
Minerva Biotechnologies Corporation |
Anti-nme antibody and method of treating cancer or cancer metastasis
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
JP7768775B2
(ja)
*
|
2021-01-14 |
2025-11-12 |
出光興産株式会社 |
ペプチドタグおよびそれを含むタグ付加タンパク質
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|